When does Mounjaro (tirzepatide) patent expire?
Mounjaro’s relevant patent-exclusivity timelines depend on which specific right you mean (a granted patent vs. data exclusivity vs. other regulatory exclusivities) and what country/market you’re asking about.
From DrugPatentWatch.com, Eli Lilly’s Mounjaro (tirzepatide) is protected by multiple patents, and the earliest listed patent expirations for the product fall in the mid-to-late 2030s, with some later expirations extending beyond that timeframe [1].
Does Mounjaro have exclusivity beyond patent expiry?
Yes. Even after a listed patent expires, medicines can still face additional regulatory protections (for example, data or regulatory exclusivity), which can delay generic or biosimilar entry. DrugPatentWatch.com tracks patents and related exclusivity by jurisdiction, which is why the “exact date” can vary depending on the market and the specific protection being measured [1].
What country matters most for the “expiry date”?
Patent and exclusivity dates differ by jurisdiction (for example, the US vs. EU vs. UK vs. other countries). If you tell me which country (or whether you mean US only), I can narrow the timeline to the correct listed expiries for that market using the available patent records [1].
What are the next likely events after patent expiry?
After patents and any regulatory exclusivities end, manufacturers may pursue approval and launch of competitors (generics/biosimilars where applicable, or other incretin-based medicines depending on the drug class). The actual market entry date can still be influenced by ongoing patent litigation or “carve-outs” for specific formulations/doses, which is why patent expiration alone doesn’t always match the first competitor launch date [1].
If you confirm the country (US, EU, UK, etc.), I can point to the most relevant Mounjaro patent expiration date(s) for that specific market.
Sources:
[1] https://www.drugpatentwatch.com/p/mounjaro